- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00746720
Modulation of the Surgical Inflammatory Response by Etoricoxib
Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be a multiple centre, double-blind, placebo-controlled, randomized, parallel group study conducted in male and female adult patients undergoing elective primary single hip arthroplasty. In part 1 of the study 12 patients will be enrolled in the study and will be administrated 120 mg Etoricoxib or placebo orally on day one post surgery. The results from part 1 should help to adjust sampling time points (for blood, cerebrospinal fluid and hip drain fluid) if necessary. In part 2 of the study 40 patients will be enrolled and should receive 120 mg etoricoxib or placebo two hours before and 24 hours after surgery.
Primary end points will be the inflammatory mediators on peripheral and central levels. After surgical manipulation we expect increased mediators on both sides. It will be investigated if the medication could reduce the mediators compared to placebo and if the effect is related to pharmacokinetic parameters.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, D-13125
- Helios Klinikum Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject undergoing elective primary single hip arthroplasty
- Subject diagnosed with Osteoarthritis / arthrosis
- Subject has not taken non-steroidal anti-inflammatory drugs within 4 of their terminal half life times prior to enrollment
- Subject capable of understanding and cooperating with the requirements of the study
Exclusion Criteria:
- Patients with renal insufficiency (serum creatinine >1.5 mg/dl)
- Recent major trauma or systemic infection (within 3 months)
- Use of corticosteroid medication or chronic opioids (within 3 months)
- Any other condition likely to affect prostaglandin and cytokine levels
- Participation in another clinical study or receipt of an investigational drug within 30 days
- Hypersensitivity to any component of the etoricoxib and/or placebo tablets
- Uncontrolled hypertension defined as systolic blood pressure >140 mm Hg and diastolic pressure >90 mm Hg at rest after two repeated measurements
- Congestive heart failure (NYHA II-IV)
- Cerebrovascular disease
- Established ischemic heart disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty)
- Patients with any kind or severity of cirrhosis of the liver or cholestasis or elevated liver function enzymes (ALT or AST 3 fold) as a sign of clinical significant liver malfunction (corresponds to any Child-Pugh-Score ≥5)
- Patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)
- Pregnancy and lactation
- Patients with active peptic ulcerations or active gastro-intestinal (GI) bleeding
- Inflammatory bowel disease
- Recent history (within the last year) of alcohol or other substance abuse
- An employee of the sponsor or study site
- Any neurological syndrome or any other condition leading to contra-indication to spinal anesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A, 1
Study part 1 (n = 8)
|
film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
Other Names:
film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
Other Names:
|
Placebo Comparator: A, 2
Study part 1 (n = 4)
|
film coated tablet (orally), two tablets once daily, on day one post surgery
Other Names:
film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
Other Names:
|
Experimental: B, 1
Study part 2 (n = 20)
|
film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
Other Names:
film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
Other Names:
|
Placebo Comparator: B, 2
Study part 2 (n = 20)
|
film coated tablet (orally), two tablets once daily, on day one post surgery
Other Names:
film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To test the hypothesis that orally administered etoricoxib (COX-2 inhibitor) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients.
Time Frame: within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2)
|
within 24 hours post dosing (study part 1) and within 48 hour post dosing (study part 2)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the CSF (cerebrospinal fluid), plasma and tissue pharmacokinetics of orally administered etoricoxib.
Time Frame: within 24 hours post dosing (study part 1) and within 48 hours post dosing (study part 2)
|
within 24 hours post dosing (study part 1) and within 48 hours post dosing (study part 2)
|
To correlate the prostaglandin and cytokine response to clinical outcome parameters after hip arthroplasty.
Time Frame: within 4 days post dosing (study part 1 and 2)
|
within 4 days post dosing (study part 1 and 2)
|
To assess the safety (via clinical laboratory tests and adverse events) of a single dose of 120 mg Etoricoxib for one day (Part1) or for two days (Part2) and placebo.
Time Frame: within 4 days post dosing (study part 1 and 2)
|
within 4 days post dosing (study part 1 and 2)
|
Collaborators and Investigators
Investigators
- Study Director: Kay Brune, MD, PhD, University of Erlangen-Nürnberg
- Principal Investigator: Josef Zacher, MD, PhD, Helios Klinikum Berlin-Buch
- Principal Investigator: Martin Fromm, MD, PhD, University of Erlangen-Nürnberg
- Principal Investigator: Asokumar Buvanendran, MD, Rush University
Publications and helpful links
General Publications
- Buvanendran A, Kroin JS, Berger RA, Hallab NJ, Saha C, Negrescu C, Moric M, Caicedo MS, Tuman KJ. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006 Mar;104(3):403-10. doi: 10.1097/00000542-200603000-00005. Erratum In: Anesthesiology. 2006 Apr;104(4):900.
- Renner B, Zacher J, Buvanendran A, Walter G, Strauss J, Brune K. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):127-36. doi: 10.1007/s00210-009-0482-0. Epub 2010 Jan 6.
- Renner B, Walter G, Strauss J, Fromm MF, Zacher J, Brune K. Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief. Eur J Pain. 2012 Jul;16(6):838-48. doi: 10.1002/j.1532-2149.2011.00062.x. Epub 2011 Dec 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Hip
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Etoricoxib
Other Study ID Numbers
- 02B2005
- EudraCT No.: 2005-003854-80
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
Clinical Trials on Etoricoxib 60 mg
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Clinica Virgen MilagrosaMerck Sharp & Dohme LLCTerminatedSoft Tissue Injuries of the Shoulder | Tenosynovitis and Bursitis Affecting the ShoulderPeru
-
Organon and CoCompleted
-
Vifor (International) Inc.Labcorp Drug Development IncWithdrawnBeta-ThalassemiaUnited States, Bulgaria, Israel
-
Grünenthal GmbHCompletedPain | Chronic Pain | Neuropathic Pain | Visceral PainGermany
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Sobi, Inc.TerminatedThrombocytopeniaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
AbbVieActive, not recruitingChronic Migraine | Episodic MigraineUnited States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom